At ImaginAB, we believe in a future without biopsies.

A future where we can utilise our advanced technology to deliver more precise, timely immune response data and demand more from predictive biomarkers, without sacrificing patient comfort.

As a market leader in next generation immune-oncology imaging, we have the expertise and innovations to make this a reality.

We exist to Challenge, Create and to Transform.

Thumbnail & Text

scan

Heading 1

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Morbi arcu nulla, dapibus et molestie eu, suscipit sed orci.

scan

Heading 2

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Morbi arcu nulla, dapibus et molestie eu, suscipit sed orci.

scan

Heading 3

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Morbi arcu nulla, dapibus et molestie eu, suscipit sed orci.

scan

Heading 4

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Morbi arcu nulla, dapibus et molestie eu, suscipit sed orci.

Clinical trial example with a catchy title

    Recruiting
    18+ years
    Male or Female
    NCT03802123

    ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumors

    United States
    • University of Alabama-Birmingham Hospital
    • CARTI Cancer Center
    • City of Hope National Medical Center
    • University of Iowa Hospitals and Clinics
    • Dana-Farber Cancer Institute
    • Karmanos Cancer Institute
    • Washington University School of Medicine
    • Memorial Sloan Kettering Cancer Center
    • Oregon Health& Science University
    • University of Pennsylvania
    Protocol IAB-CD8-201 is a Phase II, Open Label, Multi-Dose Study of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients with Advanced or Metastatic Melanoma, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck Selected to Receive Standard-of-Care Immunotherapy as Single Agent or in Combination. This study will evaluate the safety of repeat doses of ⁸⁹Zr-Df-IAB22M2C, assess and quantify any detectable changes in ⁸⁹Zr-Df-IAB22M2C uptake from Baseline to post-Treatment, establish the relationship of ⁸⁹Zr-Df-IAB22M2C uptake in tumors with CD8+ TIL density, biodistribution, evaluate the variance in participants' gene expression pre- and post-Treatment, evaluate the correlation of ⁸⁹Zr-Df-IAB22M2C uptake with clinical response by RECIST 1.1/iRECIST and evaluate the correlation of ⁸⁹Zr-Df-IAB22M2C uptake with immune infiltrates and other molecular biomarkers (CD4, CD8, PD-1 and PD-L1) expression by IHC.
Recruiting
18+ years
Male or Female
NCT03533283

An Open-Label Phase lB Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Belgium
  • UZ Gent
Denmark
  • Rigshospitalet; Fase 1 Enhed
Italy
  • Istituto Nazionale Tumori Irccs Fondazione
  • Policlinico S.Orsola-Malpighi;Istituto di Ematologia "Seragnoli"
  • ASST PAPA GIOVANNI XXIII
  • Fond. IRCCS Istituto Nazionale Tumori
Spain
  • Hospital Universitari Vall d'Hebron
  • Hospital Duran i Reynals
  • HOSPITAL DE MADRID NORTE SANCHINARRO
  • Hospital Clinico Universitario Virgen de la Victoria
  • Hospital Clinico Universitario de Valencia
UK
  • The HOPE Clinical Trials Unit
  • University College London Hospitals NHS Foundation Trust
  • The Newcastle upon Tyne Hospitals NHS Foundation Trust
This is an open-label, single arm, multicenter, dose finding, Phase Ib study in order to assess the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D) for this combination treatment and to evaluate the general safety, tolerability, pharmacokinetic (PK), pharmacodynamic, and preliminary anti-tumor activity of this combination treatment in adult patients. This study includes an additional open-label imaging feasibility sub-study using a tracer in adult participants with relpased/refractory B-cell non-Hodgkin's lymphoma to image CD8+T-cells at baseline and after treatment with glofitamab, including pre-treatment with obinutuzumab.
Not Yet Recruiting
50+ years
Male or Female
NCT04874818

CD8+ T-cell PET/CT Imaging in COVID-19 Patients (Tangelo)

Netherlands
  • Radboud University Medical Center
A subset of patients diagnosed with severe acute respiratory syndrome (SARS)-CoV2 infection present with lymphopenia. The degree of lymphopenia, and in particular reduced cluster of differentiation (CD)8+ T-cell numbers, is correlated with clinical deterioration and intensive care unit (ICU) admission. The underlying reasons for lymphopenia in coronavirus disease (COVID)-19 is currently unclear, We aim to assess differences in the in vivo distribution of CD8+ T-cells in patients with proven SARS-CoV2 presenting with lymphopenia or with normal lymphocyte counts, using Zirconium-89 ([89Zr])Df-IAB22M2C positron emission tomography (PET) imaging.
Not Yet Recruiting
18+ years
Male or Female
NCT04826393

ASP8374 + Cemiplimab in Recurrent Glioma

United States
  • Brigham and Women's Hospital
This study is looking at the safety and efficacy of the drug combination of ASP8374 with cemiplimab in people with recurrent malignant glioma. The study will be conducted in two parts, the first portion of the study will be to establish the highest dose of ASP8374 that can be given safely with cemiplimab and will be used as the recommended dose of ASP8374 in combination with cemiplimab for the second portion of the study. The second portion of the study will be to compare the effect of having ASP8374 in combination with cemiplimab prior to surgery. The names of the study drugs involved in this study are: ASP8374; Cemiplimab; 89Zr-Df-IAB22M2C (Administered as part of scan procedure)
Completed
18+ years
Male or Female
NCT03107663

⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma

United States
  • Memorial Sloan Kettering Cancer Center
  • University of Pennsylvania
  • Honor Health and Imaging Endpoints
To determine the safety and feasibility of 89Zr-Df-IAB22M2C as an immunoPET tracer; determine the best time window and protein dose for imaging; determine the pharmacokinetic (PK) and biodistribution of the probe; and to determine imaging parameters for optimal lymphoid and tumor visualization.
Recruiting
18+ years
Male or Female
NCT03802123

⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumors

United States
  • University of Alabama-Birmingham Hospital
  • CARTI Cancer Center
  • City of Hope National Medical Center
  • University of Iowa Hospitals and Clinics
  • Dana-Farber Cancer Institute
  • Karmanos Cancer Institute
  • Washington University School of Medicine
  • Memorial Sloan Kettering Cancer Center
  • Oregon Health& Science University
  • University of Pennsylvania
Protocol IAB-CD8-201 is a Phase II, Open Label, Multi-Dose Study of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients with Advanced or Metastatic Melanoma, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck Selected to Receive Standard-of-Care Immunotherapy as Single Agent or in Combination. This study will evaluate the safety of repeat doses of ⁸⁹Zr-Df-IAB22M2C, assess and quantify any detectable changes in ⁸⁹Zr-Df-IAB22M2C uptake from Baseline to post-Treatment, establish the relationship of ⁸⁹Zr-Df-IAB22M2C uptake in tumors with CD8+ TIL density, biodistribution, evaluate the variance in participants' gene expression pre- and post-Treatment, evaluate the correlation of ⁸⁹Zr-Df-IAB22M2C uptake with clinical response by RECIST 1.1/iRECIST and evaluate the correlation of ⁸⁹Zr-Df-IAB22M2C uptake with immune infiltrates and other molecular biomarkers (CD4, CD8, PD-1 and PD-L1) expression by IHC.

Clinical trials map

Text

map

Side title

Text

Title

Optional caption
scan

ImaginAb is a pioneering, innovative biotech firm and the founder of smart technology-based radiopharmaceutical solutions.

We develop advanced imaging solutions to revolutionize the Life Science and healthcare markets with modern-day alternatives to painful, outdated biopsies.

Our vision is to reimagine the future of immune oncology care paths, innovating tomorrow and assisting physicians with the precise insight they need to make smarter, more timely decisions, while delivering greater comfort and quality of life to patients.

Our ImmunoPET Imaging scans the entire body and visualizes the effects of treatments head to toe with in vivo imaging of CD8 T-cells.

In addition to this, we are also utilizing our antibody fragment platform technologies to develop best-in-class therapeutic radiopharmaceuticals.

Our team is made up of medical experts and scientific innovators and we aspire to and are confident that we will become the new standard in routine patient management; accelerating the progression of clinical trials, transforming patient care and helping people live better, healthier lives.

Button example

SNMMI

The Society of Nuclear Medicine and Molecular Imaging (SNMMI), headquartered in Reston, Va., is a nonprofit scientific and professional organization that promotes the science, technology and practical application of nuclear medicine and molecular imaging.

Benefits

Our technology has all of the advantages of antibody technology like high specificity, but by altering and reducing the size we can:

We can image quicker

We can image quicker

Instant feedback on the physical status of a patient before, during and after treatment

Multi-use technology

Multi-use technology

The technology is perfect for developing both imaging and therapy radiopharmaceuticals

Inert minibodies

Inert minibodies

The minibodies are inert and so do not change anything on binding or function in the body

Testimonials

Industry Leaders thoughts about CD8ImmunoPET

Todd Binder

Todd Binder

Chief Executive Officer, Neuvogen

89Zr CD8 Immuno-PET imaging agents provide access to "highly specific and precise imaging of the presence of CD8 T Cells in solid tumors over time."

Tabbed content

Block 1

Move from repeat painful biopsies to seeing the bigger treatment picture. CD8 ImmunoPET Imaging visualizes a patient’s real time response to treatments, resulting in increased clarity and greater care.

Block 2

Move from repeat painful biopsies to seeing the bigger treatment picture. CD8 ImmunoPET Imaging visualizes a patient’s real time response to treatments, resulting in increased clarity and greater care.

Block 3

Move from repeat painful biopsies to seeing the bigger treatment picture. CD8 ImmunoPET Imaging visualizes a patient’s real time response to treatments, resulting in increased clarity and greater care.

Block 4

Move from repeat painful biopsies to seeing the bigger treatment picture. CD8 ImmunoPET Imaging visualizes a patient’s real time response to treatments, resulting in increased clarity and greater care.

Heading 2

asdasdasda

asdsad

asdasdsa

Challenge

The conventional route to immuno oncology response, innovating for greater precision and patient care.

Create

State-of-the-art imaging solutions to equip physicians with what they need to gain in-depth knowledge of how a patient is responding to treatment.

Transform

The biotech space with pioneering alternative approaches, helping patients live better and healthier lives.

Why partner with ImaginAb

Title

Title

In the last 3 years, we have extended our operations so that we can offer clinical trials within the US, Europe and Australia.

Ttitle 2

Text

"At ImaginAb, we believe in a future without repeat painful biopsies"

Learn more about ImaginAb